Smith & Nephew reported first-half 2026 results with underlying revenue growth of 2.3% to $3,097 million and trading profit up 8.1% to $566 million. Adjusted earnings per share rose 11.0% to 47.7 cents. The company reduced its full-year revenue growth guidance from around 6% to around 4%, citing softer performance in US Orthopaedics and Advanced Wound Bioactives, while maintaining trading profit, free cash flow, and ROIC targets. Smith & Nephew announced an interim dividend of 15.6 cents per share, a 4.0% increase year-over-year. The company operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue.
